Pfizer Inc. today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide ...

Emblaveo (aztreonam-avibactam) was approved for treating complicated intra-abdominal infections with limited or no treatment ...

A series of reports released today by the European Centre for Disease Prevention and Control (ECDC) show sexually transmitted ...

There exists no ‘amyloid cabal’” in Alzheimer’s research, neurologist Dennis Selkoe writes in response to Charles Piller’s “Doctored.” ...

CAMBRIDGE, MA AND PITTSBURGH, PA / ACCESSWIRE / 10, 2025 / Next Gen Diagnostics (NGD), a pioneer in the development of machine learning models for whol ...

Alnylam awaits FDA decisions on Amvuttra & Fitusiran next month, poised to boost revenue, profitability, and share growth.

Despite a recently-agreed $7.4 billion settlement, the Sackler family has yet to fully account for its role in America's ...

The spiraling consequences underline the real-world harms from Donald Trump's upending of decades-old U.S. initiatives.

Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and growth potential. Learn why BMY stock is a solid ...

Lupkynis (voclosporin) has been cleared by the European Commission for ... Britain is expected from the UK Medicines and Healthcare products Regulatory Agency (MHRA) in the coming weeks, according ...

HOUSTON - Moleculin Biotech, Inc. (NASDAQ:MBRX), a late-stage pharmaceutical company currently trading near its 52-week low of $0.66, announced it has received the first European regulatory approval ...

From new coordination methods to more transparency over lobbying, here’s how Ursula von der Leyen reshaped the Commission in ...